ABSTRACT
INTRODUCTION
The long-acting anticholinergic, or muscarinic antagonist, tiotropium bromide (SPIRIVA Ò , Boehringer Ingelheim, Ingelheim am Rhein, Germany), improves lung function, quality of life, symptoms (dyspnea), and exercise endurance, as well as reducing exacerbations in chronic obstructive pulmonary disease (COPD) [1] [2] [3] [4] . Tiotropium is approved as a dry-powder formulation delivered via
Ingelheim, Germany; 18 lg once daily) [5] and as an aqueous solution delivered via the Respimat Ò Soft Mist TM Inhaler (Boehringer Ingelheim; 5 lg once daily, 2 puffs of 2.5 lg)
[6] in many countries. Tiotropium Respimat 5 lg and HandiHaler 18 lg have similar exacerbation and bronchodilator efficacy, safety, and pharmacokinetic (PK) profiles [7] [8] [9] [10] [11] . Several studies have compared the efficacy of tiotropium HandiHaler (18 lg) with different doses of Respimat [7] [8] [9] [10] [11] [12] [13] ; however, to date a comprehensive review of the published dataset has not yet been undertaken. This report summarizes the spirometric dose-response relationships of once-daily tiotropium given by soft mist inhalation (1.25, 2.5, 5, 10, and 20 lg) and as dry powder (18 lg), across six studies; each of these assessed trough forced expiratory volume in 1 s (FEV 1 ; defined as the difference between pre-dose FEV 1 on day 1 [baseline] and the pre-dose FEV 1 at the end of the treatment period, i.e., before the last dose) and trough forced vital capacity (FVC) as efficacy end points [7] [8] [9] [10] [11] [12] [13] . The trial durations ranged from 3 weeks [10] to 2-3 years [7] [8] [9] [10] [11] [12] [13] .
METHODS
All dose-response studies of Respimat conducted in comparison with HandiHaler were chosen for inclusion in this analysis. Detailed methods for the six studies included in this report have been published previously [7] [8] [9] [10] [11] [12] [13] .
Summary of Study Design and Statistical Analyses
Study 1 [7] In this multicenter, randomized, double-blind within device, parallel-group, placebo-controlled, 3-week dose-ranging study, 202 patients with COPD were allocated to Respimat 1.25, 2.5, 5, 10, or 20 lg, HandiHaler 18 lg, or placebo (ClinicalTrials.gov identifier: NCT02175342) [7] . The primary end point was the change from baseline in trough FEV 1 on day 21. FEV 1 and FVC measurements were taken at baseline (day 0) and on days 7, 14, and 21. 
Study 4 [9]
This randomized, double-blind, double-dummy, two-way, 4-week crossover study (ClinicalTrials.gov identifier: NCT00292448) of Respimat 5 lg and HandiHaler 18 lg was conducted in Japanese patients with COPD (n = 184; n = 157 received at least one dose of study medication) [9] . The primary end point was trough FEV 1 response from baseline to day 29; trough FVC response after 4 weeks was also assessed. Spirometry testing took place at the start (day 1) and end (day 29) of each treatment period.
Using an ANCOVA with terms for period, treatment and patient as fixed effects, and baseline FEV 1 as a covariate, Respimat 5 lg was tested for non-inferiority to HandiHaler 18 lg (one-sided test, lower bound of 95% CI compared with non-inferiority delta of -50 mL). Trough FVC response was analyzed in the same way.
Study 5 [12]
The TIOtropium Safety and Performance In Respimat
] study (ClinicalTrials.gov identifier: NCT01126437) was a randomized, double-blind, double-dummy, parallel-group, event-driven trial of 2-3 years' duration in patients with COPD, which included a substudy of 1370 patients from centers experienced in performing spirometry [12] . Trough FEV 1 was assessed by a predefined test of non-inferiority of Respimat 5 and 2.5 lg versus HandiHaler 18 lg (averaged over weeks 24-120; non-inferiority margin 50 mL).
Trough FEV 1 and FVC were measured at week 24 and every 24 weeks thereafter. For the majority of patients, spirometry measurements were available for weeks 24-120 [11] [12] [13] . Spirometry data from weeks 24 to 120 were analyzed using a restricted maximum likelihood (REML)-based repeated measures approach, including the fixed categorical effects of treatment, investigative site, visit, and treatment by visit interaction; the continuous fixed covariates of baseline and baseline by visit interaction, and a random term for patient.
Missing FEV 1 and FVC values due to worsening of COPD were imputed using worst observation carried forward. 
Compliance with Ethics Guidelines
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS

Study 1 [7]
Compared with HandiHaler 18 lg, mean adjusted trough FEV 1 response on day 21 was lower for Respimat 1.25 lg (difference -130 mL; 95% CI -251 to -9 mL; P = 0.035) and Respimat 2.5 lg (difference -182 mL; 95% CI -302 to -63 mL; P = 0.003). Mean trough FEV 1 was numerically lower than HandiHaler 18 lg for Respimat 5 lg (difference -83 mL; 95% CI -204 to 38 mL), Respimat 10 lg (difference -97 mL; 95% CI -217 to 22 mL), and Respimat 20 lg (difference -86 mL; 95% CI -207 to 34 mL; Fig. 1 Compared with HandiHaler 18 lg, the adjusted mean trough FEV 1 response on day 29 was higher for Respimat 5 lg (difference 29 mL; 95% CI 4 to 55 mL; P\0.03) and Respimat 10 lg (difference 31 mL; 95% CI 5 to 56 mL; P = 0.02; Fig. 1 ). Mean adjusted trough FVC response on day 29 was numerically higher for Respimat 5 lg compared with HandiHaler 18 lg (difference 22 mL; 95% CI -36 to 80 mL) and Respimat 10 lg compared with HandiHaler 18 lg (difference 53 mL; 95% CI -5 to 112 mL; Fig. 2 ), but these differences did not reach statistical significance.
Study 4 [9]
Mean adjusted trough FEV 1 response on day 29 was similar for Respimat 5 lg and HandiHaler 18 lg (difference versus HandiHaler: 8 mL; 95% CI -9 to 24 mL; Fig. 1 ). Non-inferiority was demonstrated with a lower confidence limit [50 mL (P\0.001). The adjusted mean trough FVC value on day 29 was also similar for Respimat 5 lg and HandiHaler 18 lg (difference -4 mL; 95% CI -44 to 36 mL; P = 0.84; Fig. 2 ).
Study 5 [12]
The adjusted mean trough (pre-dose) FEV 1 (averaged over weeks 24-120) for Respimat 5 lg was comparable to HandiHaler 18 lg (difference versus HandiHaler: -10 mL; 95% CI -38 to 18 mL), but was lower than -49 mL; 95% CI -98 to -1 mL; Fig. 2 ) [13] .
Study 6 [8]
Trough FEV 1 on day 28 was comparable to HandiHaler 18 lg for Respimat 5 lg (difference versus HandiHaler 18 lg: -7 mL; 95% CI -34 to 20 mL), but was lower than HandiHaler 18 lg for Respimat 2.5 lg (difference -27 mL; 95% CI -55 to 0 mL) and Respimat 1.25 lg (difference -41 mL; 95% CI -68 to -14 mL; Fig. 1 ). Trough FVC on day 28 was comparable to HandiHaler 18 lg for Respimat 5 lg (difference 0 mL; 95%
CI -55 to 56 mL) and numerically lower for Respimat 2.5 lg (difference -47 mL; 95% CI -103 to 9 mL) and was significantly lower than HandiHaler 18 lg for Respimat 1.25 lg (difference -97 mL; 95% CI -153 to -42 mL; [10] and Ichinose et al. [9] , and was supported by day 28 results from the Hohlfeld et al. study [8] . In another Respimat dose-ranging study (Caillaud et al. [7] ), Respimat 5 lg was the most comparable dose to HandiHaler 18 lg in terms of trough FEV 1 and adjusted trough FVC outcomes at day 21.
The effects of the Respimat 1.25 and 2.5 lg doses on the adjusted trough FEV 1 were lower than observed with HandiHaler 18 lg. Of note, the mean responses to Respimat in this study [7] were lower than observed in the other studies included in this analysis. Possible explanations for these results are the differences in study design characteristics in this study [7] , as compared to other trials reviewed in this article, including a smaller sample size, a lack of a double-dummy design and shorter treatment duration.
A limitation of the current analysis is that it compared data from studies that had some differences in their design and patient demographics. The TIOSPIR sub-study was powered to demonstrate non-inferiority testing for Respimat 2.5 and 5 lg versus HandiHaler 18 lg for trough (pre-dose) FEV 1 but not for trough FVC [13] . The studies reported by van Noord et al. [10] , Ichinose et al. [9] , and Caillaud et al. [7] used an ANCOVA (with varying adjustments) for the assessment of lung function end points, whereas the Hohlfeld et al. [8] study used an REML-based repeated-measures approach. Furthermore, the TIOSPIR [11] [12] [13] and the Ichinose et al. [9] studies did not have a placebo arm; instead, treatment differences were investigated between patients who were randomized to HandiHaler 18 lg, Respimat 2.5 and/or 5 lg.
The study by Caillaud et al. [7] only enrolled a small sample of 25-28 patients per dose and, like the study by Hohlfeld et al. [8] , was not blinded with double dummy; this needs to be taken into account when interpreting these results. The lung function response to
HandiHaler 18 lg in the study by Caillaud et al. [7] was relatively high compared with the other trials. The timing of the pulmonary function tests also differed between studies:
Caillaud et al. [7] assessed FEV 1 and FVC responses earlier at 3 weeks (in contrast to 4 weeks for the studies reported by van Noord et al. [10] , Ichinose et al. [9] , and Hohlfeld et al. [8] ; in TIOSPIR [11] [12] [13] ), pulmonary function was evaluated pre-dose (24 h after dosing the previous day), at baseline, and every 24 weeks (for the trial duration). Regarding the study populations, patients in the studies by van Noord et al. [10] had pre-bronchodilator FEV 1 \60% of predicted (compared with post-bronchodilator FEV 1 \80% predicted in the study by Hohlfeld et al. [8] , FEV 1 \70% or \80% of predicted in TIOSPIR [11] [12] [13] , FEV 1 B70% predicted in the study by Ichinose et al. [9] , and FEV 1 \65% of predicted in the study by Caillaud et al. [7] ). However, the post-bronchodilator FEV 1 /FVC ratio was \70%
in all six studies [7] [8] [9] [10] [11] [12] [13] .
CONCLUSIONS
In conclusion, the results from six tiotropium trials in COPD demonstrated a similar bronchodilator efficacy of once-daily Respimat 
